Lazard Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.08M | Buy |
42,723
+28,441
| +199% | +$4.97M | 0.01% | 456 |
|
|
2025
Q4 | $2.43M | Buy |
14,282
+640
| +5% | +$98.1K | ﹤0.01% | 788 |
|
|
2025
Q3 | $1.8M | Buy |
13,642
+6,868
| +101% | +$824K | ﹤0.01% | 896 |
|
|
2025
Q2 | $717K | Sell |
6,774
-10,027
| -60% | -$1.09M | ﹤0.01% | 1397 |
|
|
2025
Q1 | $2.08M | Buy |
16,801
+7,618
| +83% | +$994K | ﹤0.01% | 956 |
|
|
2024
Q4 | $1.13M | Sell |
9,183
-19,030
| -67% | -$2.24M | ﹤0.01% | 1104 |
|
|
2024
Q3 | $3.14M | Buy |
28,213
+28,203
| +282,030% | +$3.09M | ﹤0.01% | 752 |
|
|
2024
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 2154 |
|
|
2024
Q1 | $1K | Sell |
10
-1
| -9% | -$122 | ﹤0.01% | 1975 |
|
|
2023
Q4 | $1K | Hold |
11
| – | – | ﹤0.01% | 2204 |
|
|
2023
Q3 | $1K | Hold |
11
| – | – | ﹤0.01% | 2227 |
|
|
2023
Q2 | $1K | Buy |
+11
| New | +$1.48K | ﹤0.01% | 2254 |
|
|
2023
Q1 | – | Sell |
-390
| Closed | -$62K | – | 2427 |
|
|
2022
Q4 | $62K | Buy |
390
+2
| +0.5% | +$293 | ﹤0.01% | 1708 |
|
|
2022
Q3 | $51K | Buy |
388
+374
| +2,671% | +$56.9K | ﹤0.01% | 1793 |
|
|
2022
Q2 | $2K | Buy |
+14
| New | +$2.15K | ﹤0.01% | 2292 |
|
|
2021
Q3 | – | Sell |
-377
| Closed | -$66K | – | 2220 |
|
|
2021
Q2 | $66K | Hold |
377
| – | – | ﹤0.01% | 1490 |
|
|
2021
Q1 | $61K | Hold |
377
| – | – | ﹤0.01% | 1359 |
|
|
2020
Q4 | $62K | Hold |
377
| – | – | ﹤0.01% | 1317 |
|
|
2020
Q3 | $53K | Sell |
377
-268
| -42% | -$33.2K | ﹤0.01% | 1172 |
|
|
2020
Q2 | $71K | Sell |
645
-192
| -23% | -$21.2K | ﹤0.01% | 1116 |
|
|
2020
Q1 | $83K | Buy |
837
+331
| +65% | +$42.8K | ﹤0.01% | 1039 |
|
|
2019
Q4 | $75K | Buy |
506
+304
| +150% | +$41.4K | ﹤0.01% | 993 |
|
|
2019
Q3 | $25K | Buy |
+202
| New | +$27.1K | ﹤0.01% | 1046 |
|
|
2019
Q2 | – | Sell |
-708
| Closed | -$101K | – | 1220 |
|
|
2019
Q1 | $101K | Buy |
+708
| New | +$92.3K | ﹤0.01% | 1033 |
|
|
2017
Q1 | – | Sell |
-15
| Closed | -$1K | – | 1043 |
|
|
2016
Q4 | $1K | Buy |
15
+8
| +114% | +$891 | ﹤0.01% | 981 |
|
|
2016
Q3 | $0 | Hold |
7
| – | – | ﹤0.01% | 1020 |
|
|
2016
Q2 | $0 | Buy |
+7
| New | +$1.03K | ﹤0.01% | 1075 |
|
|
2014
Q1 | – | Sell |
-81
| Closed | -$10K | – | 1039 |
|
|
2013
Q4 | $10K | Sell |
81
-1,585
| -95% | -$164K | ﹤0.01% | 966 |
|
|
2013
Q3 | $153K | Buy |
+1,666
| New | +$134K | ﹤0.01% | 816 |
|
Other funds holding JAZZ
VPM
VCM
EC
Lazard Asset Management's JAZZ Position: Q1 2026 in Review
Lazard Asset Management increased its Jazz Pharmaceuticals (JAZZ) stake by 199% in Q1 2026, buying an estimated $4.97M and bringing the position to 42,723 shares worth $8.08M. The position accounts for 0.01% of the portfolio, ranked #456.
Lazard Asset Management first reported a position in JAZZ in Q3 2013 and has held it in 29 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Lazard Asset Management held 42,723 shares of Jazz Pharmaceuticals worth $8.08M as of Q1 2026.
- Lazard Asset Management bought 28,441 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.97M.
- Jazz Pharmaceuticals made up 0.01% of Lazard Asset Management's portfolio in Q1 2026, its #456 holding.
- Lazard Asset Management first reported a position in Jazz Pharmaceuticals in Q3 2013 and has held it in 29 quarters since.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.